Long Ideas - PropThink will host an expert interview on Thursday, April 11 (details below) to discuss the intellectual property (IP) position on Zerenex, Keryx Biopharmaceutical’s (KERX) late-stage phosphate … Continue Reading
Read nowLong Ideas - On Friday, February 1st, a report out from research firm IPD Analytics took nearly 22% out of Keryx Biopharmaceuticals (KERX) by questioning the novelty and … Continue Reading
Read nowLong Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) updated investors Thursday morning on both its Zerenex development program and its 3Q financials, reiterating that pivotal Phase 3 data for the … Continue Reading
Read nowResearch - Rockwell Medical (RMTI) reported fourth quarter and full-year 2015 results after the bell this evening. The accompanying conference call was bizarre, and the stock is … Continue Reading
Read nowResearch - Equities remain linked at the hip to the fluctuations in oil, and Thursday marked the first meaningful decoupling in the last month. According to the Wall Street Journal, over the past 20 trading days (one month) the correlation has been 0.97, the highest in 26 years.
PremiumResearch - The breakout we’ve been looking for from the biotech sector (NASDAQ’s Biotech Index Fund (IBB) is underway coming out of large-cap bio and pharma earnings over the last two days. Beats across the board have investors enthused – at least for now – about the sector as a whole.
PremiumRecap - A dual event in the obesity space this week, the U.S. FDA approved Orexigen Therapeutics’ (OREX) weight loss pill Contrave just one day before an … Continue Reading
Read now
